key: cord-0786480-p47bbvp1
authors: Clayton-Chubb, Daniel; Schneider, Daniel; Freeman, Elliot; Kemp, William; Roberts, Stuart K.
title: Comment to the letter of Bril F et al. “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?”
date: 2021-06-22
journal: J Hepatol
DOI: 10.1016/j.jhep.2021.06.014
sha: aa10c060366aaf47d77c83dd24f00dbd506ea487
doc_id: 786480
cord_uid: p47bbvp1

nan

We read with interest the recent letter published by Bril vaccine, which may be the first report of COVID-19 vaccine-associated liver injury.

As vaccination programs are being rolled out globally 2 , many clinically significant side effects are starting to be identified, such as vaccine-induced immune thrombotic thrombocytopenia 3 .

Here, we report the case of a 36-year-old Iraqi-born male physician who developed likely vaccine-induced AIH following COVID-19 vaccination. He has a past medical history of hypertension treated with olmesartan and laser eye surgery two weeks prior that required topical fluoroquinolone eye drops, 1g acetaminophen TDS, and 400mg ibuprofen TDS for one week total. He had no previous history of liver disease. Of note, he had his first dose of ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca) 26 days prior to presentation with a subsequent mild febrile reaction requiring 1g acetaminophen TDS, and 400mg ibuprofen TDS for three days. He was referred to our emergency department after a finding of markedly abnormal liver function tests on routine blood tests, and was asymptomatic at the time.

His physical examination was unremarkable. Blood tests were significant for 

Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?

Vaccine in a Nationwide Mass Vaccination Setting

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis